Physician profile
Abigail E Gass
NPI 1043531932
$1,565.99
in general payments reported to CMS, 2019-2025
21 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $27.07 · 2021: $39.52 · 2022: $322 · 2023: $98.89 · 2024: $351 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $443.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $296.53 | 2021-2025 | |
| Lilly USA, LLC | $158.22 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $98.95 | 2024-2025 | |
| Astellas Pharma US INC | $90.50 | 2024-2025 | Veozah |
| Amgen INC. | $78.70 | 2019 | |
| Pfizer INC. | $71.39 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.24 | 2019 | |
| Amarin Pharma, INC. | $41.43 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.33 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $33.42 | 2019 | |
| Phathom Pharmaceuticals, INC. | $31.78 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $25.89 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $23.64 | 2019 | |
| Allergan, INC. | $16.32 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.85 | 2024 | Jardiance, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $14.37 | 2019 | |
| Boston Scientific Corporation | $13.67 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.97 | 2022 | |
| Shire North American Group INC | $12.69 | 2019 | |
| Inogen, INC. | $7.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Gass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.